← All trials
NCT03023111
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2017
- Primary completion
- Mar 1, 2019
- Completion date
- Sep 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Federal University of BahiaLead sponsor
- Federal University of BahiaOverall official - principal investigator
- Federal University of BahiaReponsible party - principal investigator
- Instituto de Medicina Integral Professor Fernando FigueiraStudy director
- Instituto de Medicina Integral Professor Fernando FigueiraStudy chair
- Oswaldo Cruz FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.